ATE346062T1 - Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten - Google Patents

Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten

Info

Publication number
ATE346062T1
ATE346062T1 AT01925946T AT01925946T ATE346062T1 AT E346062 T1 ATE346062 T1 AT E346062T1 AT 01925946 T AT01925946 T AT 01925946T AT 01925946 T AT01925946 T AT 01925946T AT E346062 T1 ATE346062 T1 AT E346062T1
Authority
AT
Austria
Prior art keywords
substituent
group optionally
chem
salt
compound represented
Prior art date
Application number
AT01925946T
Other languages
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE346062T1 publication Critical patent/ATE346062T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70Sulfur atoms
    • C07D277/74Sulfur atoms substituted by carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70Sulfur atoms
    • C07D277/76Sulfur atoms attached to a second hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01925946T 2000-04-28 2001-04-26 Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten ATE346062T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000128760 2000-04-28

Publications (1)

Publication Number Publication Date
ATE346062T1 true ATE346062T1 (de) 2006-12-15

Family

ID=18638152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925946T ATE346062T1 (de) 2000-04-28 2001-04-26 Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten

Country Status (10)

Country Link
US (1) US6982275B2 (de)
EP (1) EP1277752B1 (de)
KR (1) KR100775802B1 (de)
CN (1) CN1193024C (de)
AT (1) ATE346062T1 (de)
AU (1) AU2001252595A1 (de)
CA (1) CA2407208C (de)
DE (1) DE60124692T2 (de)
ES (1) ES2273829T3 (de)
WO (1) WO2001083473A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2417311C (en) 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
KR20100002278A (ko) 2000-12-01 2010-01-06 다케다 야쿠힌 고교 가부시키가이샤 (r)- 또는 (s)-란소프라졸의 결정
US8105626B2 (en) 2001-10-17 2012-01-31 Takeda Pharmaceutical Company Limited Granules containing acid-unstable chemical in large amount
US20050148634A1 (en) * 2002-03-29 2005-07-07 Zeria Pharmaceutical Co., Ltd 1-N-Aminobenzimidazole derivatives
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1552833B1 (de) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Herstellung eines amorphen, optisch aktiven Isomers von Lansoprazol
US7507829B2 (en) 2002-12-19 2009-03-24 Teva Pharmaceuticals Industries, Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
MXPA05013316A (es) 2003-06-10 2006-03-17 Teva Pharma Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol.
US7005732B2 (en) * 2003-10-21 2006-02-28 Honeywell International Inc. Methods and systems for providing MEMS devices with a top cap and upper sense plate
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
EP1768668A2 (de) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multi-ppi-dosierform
EP1790647B1 (de) 2004-09-13 2013-05-08 Takeda Pharmaceutical Company Limited Verfahren zur herstellung von oxidierter verbindung
ATE443051T1 (de) * 2004-10-11 2009-10-15 Ranbaxy Lab Ltd Verfahren zur herstellung substituierter sulfoxide
EP2275088B2 (de) 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Verfahren zur Granulatherstellung
DE102005061720B3 (de) * 2005-12-22 2006-10-19 Ratiopharm Gmbh Enantioselektive Herstellung von Benzimidazolderivaten und ihren Salzen
WO2007074909A1 (ja) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited 放出制御固形製剤
CN1810803B (zh) * 2006-02-17 2010-11-17 中国科学院上海有机化学研究所 高对映体选择性制备(s)-奥美拉唑的方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
EP2065379A4 (de) 2006-10-13 2011-01-19 Eisai R&D Man Co Ltd Benzimidazolverbindung mit magensäure-sekretion verhindernder aktivität
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
MX2009013162A (es) * 2007-07-12 2010-01-15 Evonik Rohmax Additives Gmbh Proceso mejorado para la preparacion de copolimeros de composicion variable continuamente.
WO2009066321A2 (en) * 2007-10-03 2009-05-28 Ipca Laboratories Limited Process for optically active sulfoxide compounds
CN102014638A (zh) * 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
EP2264024A1 (de) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Verfahren zur Herstellung einer enantiomerisch-angereicherte Protonpumpenhemmer
IT1391776B1 (it) 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
WO2010095144A2 (en) * 2009-02-04 2010-08-26 Msn Laboratories Limited Process for the preparation of proton pump inhibitors
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
IT1395118B1 (it) 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
CN102399212B (zh) * 2010-08-23 2014-07-16 江苏豪森医药集团有限公司 一种右兰索拉唑晶型及其制备方法
WO2012074110A1 (ja) 2010-12-03 2012-06-07 武田薬品工業株式会社 口腔内崩壊錠
US20130273157A1 (en) 2010-12-27 2013-10-17 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
CA2857457C (en) 2011-11-30 2018-05-01 Takeda Pharmaceutical Company Limited Dry coated tablet
SG11201509439SA (en) 2013-05-21 2015-12-30 Takeda Pharmaceutical Orally disintegrable tablet
CN104177336A (zh) * 2013-05-28 2014-12-03 上海汇伦生命科技有限公司 一种对映选择性合成右兰索拉唑的方法
CN105017216A (zh) * 2014-04-16 2015-11-04 天津药物研究院 右兰索拉唑晶型iii及其制备方法和用途
US10307748B2 (en) 2014-12-26 2019-06-04 The University Of Tokyo Method for producing proton pump inhibitor compound having optical activity
CN106083819A (zh) * 2016-06-08 2016-11-09 扬子江药业集团有限公司 一种奥美拉唑的制备方法
CN116178342A (zh) * 2022-12-26 2023-05-30 湖南欧亚药业有限公司 一种右兰索拉唑对映异构体制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
JP3929607B2 (ja) 1997-07-23 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体の製造方法
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
AU5705700A (en) 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
WO2001014366A1 (en) * 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Process for the preparation of optically active sulfoxide derivatives

Also Published As

Publication number Publication date
DE60124692D1 (de) 2007-01-04
CN1426406A (zh) 2003-06-25
KR20020092457A (ko) 2002-12-11
US20030171591A1 (en) 2003-09-11
US6982275B2 (en) 2006-01-03
ES2273829T3 (es) 2007-05-16
WO2001083473A1 (en) 2001-11-08
EP1277752A4 (de) 2005-01-12
AU2001252595A1 (en) 2001-11-12
DE60124692T2 (de) 2007-09-13
CA2407208C (en) 2010-08-17
EP1277752A1 (de) 2003-01-22
EP1277752B1 (de) 2006-11-22
CA2407208A1 (en) 2002-10-22
KR100775802B1 (ko) 2007-11-12
CN1193024C (zh) 2005-03-16

Similar Documents

Publication Publication Date Title
DE60124692D1 (de) Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten
ATE475634T1 (de) Verfahren zur herstellung von isopulegol
ATE282020T1 (de) Verfahren zur herstellung von 2-aminomalonsäure- derivaten
ATE442363T1 (de) Verfahren zur herstellung von pyridinverbindungen
DE69915713D1 (de) Verfahren zur herstellung von citalopram
ATE416158T1 (de) Verfahren zur herstellung von amidderivaten und ihren zwischenverbindungen
ATE343385T1 (de) Verfahren zur herstellung von donepezil
ATE288891T1 (de) Verfahren zur herstellung von amid-derivaten und ihren zwischenverbindungen
DE50212728D1 (de) Verfahren zur herstellung von 2-azetidinonderivaten
ATE191461T1 (de) Verfahren zur herstellung von alkoxyimino acetamid-derivaten
DE60022416D1 (de) Verfahren zur Herstellung von 2-Alkyl-3-aminothiophen Derivate und 3-Aminothiophen Derivate
FR2702220B1 (fr) Dédoublement enzymatique de dérivés de 4-alkyl-2-pipéridine-carboxylate et utilisation des composés obtenus, comme intermédiaires de synthèse.
DE69714749D1 (de) Verfahren zur herstellung von 3-amino-2-hydroxy-1-propylethern
DE69800073D1 (de) Verfahren zur Herstellung von 2-Cyanobiphenyl-Verbindungen
DE69928610D1 (de) Verfahren zur Herstellung von 2-Carbamoyl-Pyridinen
ATE345325T1 (de) Verfahren zur herstellung von derivaten der cyanobenzoesäure
DE69223016D1 (de) Verfahren und Zwischenprodukte für die Herstellung von 6-Fluorbenzisothiazolen
DE60144570D1 (de) Verfahren zur herstellung von optisch aktiven sulfonamiden und zwischenprodukte zur deren synthese
DE60124831D1 (de) Ein verfahren zur herstellung substituierter alkylamin-derivate
DE60008561D1 (de) Verfahren zur herstellung von oxazol-derivaten
DE69904652D1 (de) Verfahren zur Herstellung von optisch aktiven Aminoalkoholen
ATE244228T1 (de) Verfahren zur herstellung von chloroacetylaminothiazoleaceticsäure derivate
ATE329917T1 (de) 1h-pyrrolo 1,2-bö 1,2,4ötriazolederivate, zwischenprodukte und verfahren zur herstellung von 1h-1,2,4,-triazol-5-yl essigsäureesterderivate
DE69909460D1 (de) Verfahren zur herstellung von arylsulfenylhalogeniden
DE69108587D1 (de) Verfahren und Zwischenprodukte zur Herstellung von optisch aktiven Chromanderivaten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1277752

Country of ref document: EP